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CHAPTER 5
The optimal protocol for 
measuring an albuminuria 
class transition in clinical trials 







Albuminuria class transition (normo- to micro- to macroalbu-
minuria) is used as a surrogate endpoint to assess renoprotec-
tive drug efficacy. Current definitions of such class transition 
vary between trials in: number of urine collections, requirement 
of a confirmation visit and if so at what time, and the require-
ment of a minimal percentage albuminuria from baseline. We 
evaluated these different approaches to obtain the most optimal 
protocol.
Methods:  
Four clinical trials testing the effect of renin-angiotensin-aldo-
sterone-system intervention on albuminuria class transition in 
diabetic patients were included: BENEDICT, DIRECT, ALTITUDE 
and IRMA-2. Each trial used a different class transition defini-
tion based on: 1) either 1, 2, or 3 consecutively collected urine 
samples at each study visit, 2) different time intervals between 
study visits, 3) requirement of an additional visit to confirm the 
class transition, and 4) requirement of a percentage increase in 
albuminuria from baseline in addition to the class transition. 
We tested the effect of these different definitions on drug effica-
cy outcomes by Cox regression analysis.
 Results:  
Neither increasing the number of urines collected at a single 
study visit, nor the time interval between study visits, nor the 
requirement of a subsequent confirmation visit, nor the addition 
of a minimal percentage albuminuria change from baseline 
altered the average drug effect. However, the standard error of 
the treatment effect increased (decreased precision) with strict-
er endpoint definitions resulting in a loss of statistical signifi-
cance.
Conclusion:  
The optimal albuminuria transition endpoint for use in drug 
intervention trials can use a single urine collection for albumin-
uria assessment per study visit, without confirmation of the end 
point, and with no requirement of a minimal percentage change 
in albuminuria from baseline.
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Introduction
Transition in albuminuria class (normo- to micro- or micro- to 
macroalbuminuria) is a hallmark of progression of diabetic kidney 
disease.1,2 This hallmark has been used as an endpoint in clinical 
trials to assess renoprotective efficacy of clinical interventions. Since 
there is no standardized protocol how to measure an albuminuria 
class transition, different definitions have been used in past trials3-8 
, varying in the way urine was collected (first morning void vs. spot 
urine),3,8 how albuminuria was expressed (urinary albumin excretion 
or albumin:creatinine ratio),3,6,8 the frequency and interval of urine 
collections to define a class transition,4,3,6 as well as the requirement 
for a confirmatory visit.3,4 Confirmation at a subsequent visit may be 
important, since albuminuria is known to show a large day-to-day 
variability.9,10 To ensure that a class change is not due to chance, the 
end point definition is often complemented with a requirement that 
albuminuria increase should be greater than a predefined percentage 
of baseline.3,4
Harmonization of the endpoint criteria for the optimal definition 
of class transition in albuminuria is important for the design of fu-
ture clinical trials. Defining a transition by a single measurement and 
without a predefined percentage change may increase the number 
of endpoints and thereby the statistical power to assess drug effects. 
However, a predefined percentage change and a subsequent confirma-
tory visit may decrease the number of endpoints but may increase the 
precision of the transition and thereby increase statistical power to 
assess drug effects. 
The aim of this study was therefore to weigh the importance of all 
these opposing effects in a post-hoc analysis of completed clinical tri-
als, which tested the effects of RAAS-inhibition on albuminuria class 
transitions. The objective was to determine the optimal definition 
for a transition in albuminuria class regarding the frequency of urine 
collections, the interval between study visits for urine collections, the 
requirement of confirmatory visits, and the cut-off threshold for the 





Patients and clinical trials 
Data from four randomized controlled clinical trials in patients 
with type 1 or type 2 diabetes were analyzed: BENEDICT (Bergamo 
Nephrologic Diabetes Complications Trial), DIRECT (The Diabetic 
Retinopathy Candesartan Trials), ALTITUDE (Aliskiren Trial in Type 
2 Diabetes Using Cardio-renal Endpoints), and IRMA-2 (Irbesartan 
in patients with type 2 diabetes and Microalbuminuria) trials were 
included in this study. All trials assessed the effect of intervention 
in the renin-angiotensin-aldosterone-system on progression of 
albuminuria. The study designs and results of each trial are reported 
elsewhere and here briefly described .3,6,11-13
In the BENEDICT trial 1209 patients with type 2 diabetes, normo-
albuminuria (urinary albumin excretion rate < 20µg/min) and serum 
creatinine ≤ 1.5mg/dL were randomly allocated to placebo or active 
treatment with either verapamil (240 mg/day), trandolapril (2mg/day) 
or the combination of verapamil 180 mg/day and trandolapril 2mg/
day. Since the effect of trandalopril and trandolapril/verapamil in 
delaying progression to microalbuminuria were similar, we combined 
both treatment arms in order to increase statistical power and com-
pared against placebo. Patients with microalbuminuria at baseline 
were excluded from analysis. Urinary albumin excretion was assessed 
at randomization and every six months during the 3.6 years median 
follow-up.4 
The DIRECT trial was a clinical trial program consisting of three 
clinical trials in 3326 type 1 diabetes patients with or without retinop-
athy and in 1905 type 2 diabetes patients with retinopathy. Patients 
had normo-albuminuria (urinary albumin excretion rate < 20µg/min) 
and serum creatinine ≤ 1.5mg/dL and ≤ 1.1mg/dL (for men and wom-
en respectively). In the DIRECT trial patients were randomly allocated 
to placebo or treatment with candensartan (16 mg/day increasing to 
32 mg/day according to tolerability) and followed for a median time 
of 4.7 years. Albuminuria was assessed at randomization and yearly 
during follow-up.5 Patients with missing baseline albuminuria or 
microalbuminuria at baseline were excluded from analysis leaving 
3095 type 1 and 1795 type 2 diabetes patients available for analysis.
The ALTITUDE trial was a randomized, double-blind, placebo-con-
trolled trial enrolling 8561 patients with type 2 diabetes mellitus at 
high risk for cardiovascular and renal events. Eligible patients had 
either persistent macroalbuminuria (defined in this trial as urinary 
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albumin/creatinine ratio (UACR) ≥200 mg/g), or an estimated glomer-
ular filtration rate (eGFR) ≥30 to ≤60 mL/min/1.73m2 combined with 
either persistent microalbuminuria (UACR ≥20 mg/g to ≤200) mg/g or 
a history of cardiovascular disease. Patients were randomly assigned 
to aliskiren 300 mg/day or matched placebo in addition to an optimal 
recommended dose of an angiotensin converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB).  For the purpose of this 
study we excluded patients in the ALTITUDE trial who had UACR 
> 300 mg/g at baseline (n=4493) and those with missing baseline 
albuminuria measurements or no follow-up measurements (n=384) 
leaving 3654 patients available for analysis. Albuminuria was assessed 
at randomization, every 3 months during the first year and every 6 
months thereafter. Randomized patients were followed for a median 
of 32.9 months for occurrence of cardiovascular and renal events.6 
In the IRMA-2 trial, 590 patients with type 2 diabetes, micro-al-
buminuria (urinary albumin excretion rate > 20 to 200µg/min) and 
serum creatinine ≤ 1.5mg/dL and ≤ 1.1mg/dL (for men and women 
respectively) were enrolled. Patients were randomly allocated to either 
placebo or active treatment with irbesartan 150mg/day or 300mg/day. 
For the purpose of analysis we combined the two irbesartan treat-
ment arms to increase statistical power. Urinary albumin excretion 
was assessed at randomization and every six months during the 2 
years follow-up.3 We included 565 patients without macroalbuminuria 
at baseline.
Urine collections and albuminuria measurements 
The frequency of urine collections (single, double, or triple) per study 
visit as well as albuminuria assessment (i.e. spot or timed collection) 
differed in the four trials. In BENEDICT and ALTITUDE three consec-
utive urine collections for albuminuria assessment were performed 
at each study visit. In DIRECT two consecutive urine collections were 
performed at each study visit starting the day prior to the study visit. 
In IRMA-2 only single urine collections were performed at each study 
visit. In BENEDICT and ALTITUDE urinary albumin and creatinine 
were measured in first morning void urine collections. In DIRECT 
and IRMA-2 timed overnight urine collections were performed and 
urinary albumin excretion was measured. In each trial urinary al-
bumin and creatinine were measured in a central laboratory. In this 
study we defined microalbuminuria as a UACR of 30 mg/g or urinary 
albumin excretion of 20 µg/min. Macroalbuminuria was defined as a 





Baseline characteristics are presented as mean and standard devi-
ation for continuous variables and as counts and proportions for 
discrete variables. Non-parametric data are presented as median and 
interquartile range. The number of albuminuria class transitions 
(progression from either normo- to micro or micro- to macroalbu-
minuria) were recorded and incidence rate per 100 patient years was 
calculated. The effects of randomized treatment on all endpoint 
definitions were estimated from unadjusted Cox proportional hazard 
models, based on the intention to treat principle. For participants 
who experienced more than one event during follow-up, survival time 
to the first relevant endpoint was used in each analysis. Participants 
were censored at their date of death or, for those still alive, at the 
end of follow-up. The magnitude of the treatment effect is reflected 
by the hazard ratio and the precision of the treatment effect by its 
95% confidence interval. We first determined whether increasing the 
number of consecutive urine collections at a single visit would lead 
to a more significant treatment effect. We subsequently determined 
the effect of the time-interval between visits, the addition of a confir-
matory visit, and the addition of a percentage change in albuminuria 
from baseline using the number of urine collections as defined in the 
first step. Unscheduled visits for albuminuria measurements were not 
included in the drug efficacy analyses. All analyses were performed 
using SAS 9.3. A two sided p-value < 0.05 was considered to indicate 
statistical significance.
Results
Baseline characteristics of included trials are published elsewhere 
and are summarized in Table 1.3,11,12,14 
Number of endpoints 
Increasing the number of urine collections per visit reduced the 
number of endpoints (Table 2). The number of endpoints further de-
creased in each trial when the transition endpoint required a confir-
mation at a subsequent visit (Table 2). Adding increasing percentages 
of albuminuria change to the endpoint definition only marginally 
reduced the number of endpoints in each trial (Table 2). 
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Number of urine collections at a single visit and time interval 
between visits 
Increasing the number of urine collections at a single visit only had 
minimal effect on the average treatment effect and 95% confidence 
interval in the BENEDICT, DIRECT and ALTITUDE trials (Figure 1). 
For example, in the BENEDICT trial, the hazard ratio was 0.60 (95%CI 
0.40 to 0.89) when the transition endpoints were calculated from the 
geometric mean of three consecutive urine samples at each visit and 
0.66 (95%CI 0.46 to 0.99) based on single urine samples. Increasing 
the time interval between study visits for albuminuria assessment 
had no effect on the magnitude of the average treatment effect while 
the  precision of the drug effect estimate decreased somewhat as in-
dicated by the wider confidence intervals (Supplement Figure 1).















397 (53.5) 1769 (57.2) 1022 (58.1) 2497 (68.3) 391 (69.2)
Age (years) 61.9 (8.0) 30.9 (8.3) 30.3 (8.1) 65.8 (9.4) 58.1 (8.6)
Diastolic BP 
(mmHg)
88.8 (7.7) 73.1 (7.0) 72.7 (7.0) 74.1 (10.0) 89.6 (9.3)
Systolic BP  
(mmHg)
152.4 (14.0) 116.8 (9.7) 116.8 (9.6) 138.2 (16.3) 152.7 (14.6)
Albuminuria* 5.2  
[3.5 – 8.8] † 
4.5  
[3.5 – 7.0] †
4.5  





HbA1c (%) 3.0 (1.4) 8.3 (1.6) 8.1 (1.6) 7.9 (1.7) 7.0 (1.7)
Tot. cholesterol 
(mg/dL)
211.8 (36.5) 184.8 (37.5) 183.3 (38.7) 170.5 (46.4) 223.2 (44.4)
eGFR  
(mL/min/1.73m2) 
81.4 (15.3) 80.4 (13.7) 80.5 (14.2) 55.4 (20.6) 70.5 (12.4)










Mean of 2  
measurements





BENEDICT 123 (5.9) 107 (5.1) 98 (4.1) 14 (0.7) 
DIRECT (T1D) 417 (3.3) 344 (2.7) Na 98 (1.0)
DIRECT (T2D) 404 (6.0) 376 (5.5) Na 153 (2.7)
Micro- to macroalbuminuria
IRMA-2† 114 (12.6) Na Na 26 (3.8)
Normo- to micro- and micro- to macroalbuminuria
ALTITUDE 1861 (33.1) 1738 (29.4) 1720 (28.8) 1087 (21.0)
10% change in albuminuria in addition to a transition
Normo- to microalbuminuria
BENEDICT 123 (5.9) 107 (5.1) 98 (4.1) 14 (0.7)
DIRECT (T1D) 416 (3.3) 344 (2.7) Na 98 (1.0)
DIRECT (T2D) 404 (6.0) 376 (5.5) Na 153 (2.7)
Micro- to macroalbuminuria
IRMA-2 114 (12.6) Na Na 26 (3.8)
Normo- to micro- and micro- to macroalbuminuria
ALTITUDE 1858 (33.0) 1731 (29.3) 1716 (28.7) 1078 (20.7)
20% change in albuminuria in addition to a transition
Normo- to microalbuminuria
BENEDICT 122 (5.8) 107 (5.1) 96 (4.0) 14 (0.7) 
DIRECT (T1D) 415 (3.2) 343 (2.7) Na 98 (1.0)
DIRECT (T2D) 404 (6.0) 376 (5.5) Na 152 (2.7)
Micro- to macroalbuminuria
IRMA-2 113 (12.5) Na Na 26 (3.8)
Normo- to micro- and micro- to macroalbuminuria
ALTITUDE 1849 (32.7) 1719 (29.0) 1698 (28.3) 1078 (20.7)
30% change in albuminuria in addition to a transition
Normo- to microalbuminuria
BENEDICT 120 (5.7) 103 (4.9) 95 (4.0) 13 (0.7)
502449-L-sub01-bw-Kropelin
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DIRECT (T1D) 413 (3.2) 341 (2.6) Na 98 (1.0)
DIRECT (T2D) 403 (6.0) 374 (5.5) Na 151 (2.7)
Micro- to macroalbuminuria
IRMA-2 113 (12.5) Na Na 25 (3.6)
Normo- to micro- and micro- to macroalbuminuria
ALTITUDE 1826 (32.0) 1704 (28.6) 1687 (27.9) 1078 (20.7)
40% change in albuminuria in addition to a transition
Normo- to microalbuminuria
BENEDICT 115 (5.5) 102 (4.9) 93 (3.9) 13 (0.7)
DIRECT (T1D) 412 (3.2) 340 (2.6) Na 98 (1.0)
DIRECT (T2D) 401 (5.9) 371 (5.5) Na 147 (2.6)
Micro- to macroalbuminuria
IRMA-2 111 (12.3) Na Na 24 (3.5)
Normo- to micro- and micro- to macroalbuminuria
ALTITUDE 1796 (31.2) 1683 (28.0) 1668 (27.4) 1078 (20.7)
*Confirmation of transition endpoint at a subsequent study visit. The confirmation is based on a single 
urine sample obtained at the initial and confirmation visit. 
†In the IRMA-2 trial only single urine collections were performed at each visit
Figure 1. Magnitude and precision of the drug effect estimate according the number of urine col-
lections at a single study visit. Solid circles represents the estimate of the treatment effect and the 
horizontal line indicates the 95% confidence interval. 
Favours Favours
RAASi Placebo RAASi Placebo
BENEDICT
1 urine collection 74/14.5 49/21.0
2 urine collections 63/12.4 44/18.9
3 urine collections 57/11.2 41/17.6
DIRECT Type 1
1 urine collection 209/13.6 208/13.4 1.00 ( 0.82 - 1.21 )
2 urine collections 164/10.7 180/11.6 0.90 ( 0.73 - 1.12 )
DIRECT Type 2
1 urine collection 186/21.1 218/24.9 0.81 ( 0.66 - 0.98 )
2 urine collections 171/19.4 205/23.4 0.79 ( 0.64 - 0.97 )
ALTITUDE
1 urine collection 850/46.4 1011/54.6 0.79 ( 0.72 - 0.86 )
2 urine collections 789/43.0 949/52.1 0.80 ( 0.73 0.88 )
3 urine collections 778/42.3 942/50.6 0.78 ( 0.71 0.86 )
No / % of   events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 ( 0.46 - 0.99 )
0.61 ( 0.42 - 0.90 )
0.60 ( 0.40 - 0.89 )






Requirement for confirmation visits and time interval of the 
confirmation visit 
Addition of a confirmation visit to firmly establish the class transition 
only minimally affected the average treatment effects of trandolapril, 
candesartan, irbesartan or aliskiren (Figure 2). However, the precision 
of the drug effect estimate markedly decreased as reflected by the wid-
er 95% confidence interval in all trials. For example, in the BENEDICT 
study, the hazard ratio was 0.66 (95%CI 0.46 to 0.99) when the transi-
tion endpoints were not confirmed and 0.60 (95%CI 0.21 to 1.70) with 
confirmation. Despite the different time intervals of the confirmatory 
visit, a decrease in precision occurred in all trials suggesting that the 
timing of the confirmatory visit had no impact on the result.
Percentage increase in albuminuria 
Enhancing the level of minimal percentage change in albuminuria 
from baseline from 10% to 40% had minimal impact on the average 
and standard error of the treatment effects of trandolapril, candesar-
tan, irbesartan or aliskiren (Figure 3). For example in the BENEDICT 
study, the hazard ratio was 0.66 (95%CI 0.46 to 0.94) with 10% increase 
in albuminuria in addition to the class transition and 0.68 (95%CI 
0.46 to 0.94) with 40% increase in albuminuria.
Figure 2. Figure 2: Magnitude and precision of the drug effect estimate with a single urine collection 
and unconfirmed and confirmatory visit. Solid circles represents the estimate of the treatment effect 
and the horizontal line indicates the 95% confidence interval. 
Favours Favours
RAASi Placebo RAASi Placebo
BENEDICT
unconf irmed 74/14.5 49/21.0
conf irmed 8/1.7 6/2.8
DIRECT Type 1
unconf irmed 209/13.6 208/13.4 1.00 ( 0.82 - 1.21 )
conf irmed 48/3.2 50/3.4 0.96 ( 0.65 - 1.43 )
DIRECT Type 2
unconf irmed 186/21.1 218/24.9 0.81 ( 0.66 - 0.98 )
conf irmed 75/8.8 78/9.3 0.95 ( 0.69 - 1.30 )
IRMA-2
unconf irmed 64/17.2 50/26.3
conf irmed 14/4.0 12/7.0
ALTITUDE
unconf irmed 850/46.4 1011/54.6 0.79 ( 0.72 - 0.86 )
conf irmed 458/26.3 629/35.5 0.71 ( 0.63 0.80 )
No. / % of   events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
-
0.66 ( 0.46 - 0.99 )
0.60 ( 0.21 - 1.70 )
0.59 ( 0.41 0.86 )
0.51 ( 0.23 1.10 )
-
-
0.2 0.3 0.5 0.8 1 1.2 1.5 2
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Discussion
Transition of albuminuria class may become a more and more impor-
tant (surrogate) end point to evaluate renoprotective drug effects. Its cur-
rent use shows a wide variety of definitions of such an albuminuria class 
transition. The variations concerned the number of albuminuria col-
lections per visit, the interval of study visits for albuminuria collection, 
the addition of a class-change-conformation visit, and the addition of a 
minimal percentage albuminuria change with the class transition. We 
established in a post hoc analysis of four randomized controlled clinical 
Figure 3. Magnitude and precision of the drug effect estimate with a single urine collection and 
various increases in percentage change in albuminuria on top of the class transition. Solid circles 
represents the estimate of the treatment effect and the horizontal line indicates the 95% confidence 
interval. 
Favours Favours








0% 209/13.6 208/13.4 1.00 ( 0.82 - 1.21 )
10% 209/13.6 207/13.3 1.00 ( 0.83 - 1.22 )
20% 209/13.6 206/13.2 1.01 ( 0.83 - 1.22 )
30% 207/13.6 206/13.2 1.00 ( 0.82 - 1,21 )
40% 207/13.6 205/13.2 1.00 ( 0.83 - 1.22 )
DIRECT Type 2
0% 186/21.1 218/24.9 0.81 ( 0.66 - 0.98 )
10% 186/21.1 218/24.9 0.81 ( 0.66 - 0.98 )
20% 186/21.1 218/24.9 0.80 ( 0.66 - 0.98 )
30% 185/21.0 218/24.9 0.80 ( 0.66 - 0.97 )








0% 850/46.4 1011/54.6 0.79 ( 0.72 - 0.86 )
10% 848/46.3 1010/54.6 0.79 ( 0.72 - 0.86 )
20% 844/46.1 1005/54.2 0.79 ( 0.72 - 0.87 )
30% 828/45.2 998/53.9 0.78 ( 0.71 - 0.86 )
40% 815/44.5 981/52.9 0.78 ( 0.71 - 0.86 )
No. / % of   events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 ( 0.46 - 0.99 )
0.66 ( 0.46 - 0.94 )
0.67 ( 0.47 - 0.97 )
0.65 ( 0.45 - 0.94 )
0.68 ( 0.47 - 0.94 )
0.59 ( 0.41 - 0.86 )
0.59 ( 0.41 - 0.86 )
0.61 ( 0.42 - 0.88 )
0.61 ( 0.42 - 0.88 )
0.63 ( 0.43 - 0.92 )




trials that none of these variations had a significant impact on most of 
the outcome parameters in the different studies. These data suggest 
that single urine collections at a study visit are sufficient to define a 
transition in albuminuria as an endpoint in clinical trials. 
Because of the within individual day-to-day fluctuations in albu-
minuria prior clinical trials have used the average albuminuria from 
three consecutive instead of one urine collection at each study visit to 
determine a transition in albuminuria stage. In our study we found 
that decreasing the number of urine samples at a single visit led to 
a small increase in the number of endpoints, but the average drug 
effect and the precision of the drug effect did not change. An increase 
in the number of endpoints would be expected to result in an increase 
in precision of the drug effect estimate (decreased standard error) and 
increase in statistical significance. Yet, this did not occur possibly 
because using single compared to triple urine samples to define the 
endpoint may have introduced random noise and false positive end-
points. These two effects may have balanced each other so that the 
average and confidence intervals of the drug effect estimate did not 
change. This finding is in line with our previous study demonstrating 
that increasing the number of urine samples at a single visit had a 
modest effect on the precision of the albuminuria lowering drug 
effect estimate.15 
The results suggest that a time-interval of 6 months between study 
visits resulted in treatment effects of larger statistical significance 
compared to a 12 month time-interval between study visits. Unfortu-
nately, urine collections did not occur more frequently than every 6 
months in all trials. We were therefore unable to determine whether 
shorter time-intervals between visits would lead to more significant 
treatment effects. This needs to be addressed in future studies.  
Another approach that has been used in clinical trials to atten-
uate the impact of the within individual day-to-day fluctuations in 
albuminuria on the transition endpoint has been the requirement 
of a confirmation of the albuminuria transition. The addition of a 
confirmatory visit is expected to decrease the random noise in the 
treatment effect due to albuminuria fluctuations and false positive 
transitions. However, our analysis showed that adding a confirmatory 
visit to the endpoint definition led to a marked decrease in endpoints 
and decrease in precision of the drug effect estimates. The marked 
decrease in endpoints apparently overruled the potential gain in 
statistical power due to the removal of false-positive transitions. The 
timing of the confirmation visit for the albuminuria transition dif-
502449-L-sub01-bw-Kropelin
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fered in each trial but the results were consistent regardless at what 
time the confirmation visit was conducted.  
Previous trials have added a 30% increase in albuminuria when the 
transition occurs as a third strategy to lessen the influence of day-to-
day albuminuria fluctuations and endpoint occurrence due to chance, 
particularly for patients whose baseline albuminuria levels are close 
to the transition threshold. The first trial that added a 30% increase 
in albuminuria when the transition occurs was a trial on the effect of 
captopril in patients with type 1 diabetes.16 Although it seems logical 
to add a percentage increase in albuminuria to the endpoint defini-
tion to avoid that people close to the border of a class, can have class 
change with very small albuminuria changes, our results indicate 
that it had no effect on the number of endpoints, the average drug 
effect, nor on the precision of the drug effect. 
The question is whether a transition in albuminuria class, a surro-
gate, represents a hard outcome, and if so, whether a single-urine-de-
termined-transition is as good as two or three-consecutive-urine 
determined transitions for hard outcome prediction. Indeed in a 
post-hoc analysis of the ALTITUDE trial we found that transition in 
albuminuria predicts renal and cardiovascular outcome (Supplement 
Table 1). In addition, the predictive power was independent of all 
different definitions that we used for the albuminuria class transition 
(Supplement Table 1). These data support using single urine samples 
at a single visit to define a transition endpoint.  
Standardization of clinical trial endpoint definitions is important 
for drug regulators, physicians, and patients to assess and compare 
clinical trial results and to interpret drug efficacy. Surprisingly, all 
past clinical trials have used different definitions for a class transition 
in albuminuria endpoint. The trials differed in the number of urine 
collections at each visit to determine urinary albumin excretion, the 
method of urine collection (timed overnight collections, first morning 
void collections), correction of urinary albumin concentration by 
urinary creatinine concentration, and requirement of a confirmation 
of the albuminuria transition. Due to the different definitions we 
unified the endpoint definitions across all included trials in order to 
compare different trial results. Since we standardized the endpoint 
definitions for the included trials, our results may differ from the 
published results in the original publications. 
These results may at first sight contrast our previous findings in 
which we concluded that increasing the frequency of urine collections 




tical power to detect an albuminuria lowering drug effect. However, 
there are important differences between these studies. Firstly, the 
endpoints between the studies were different. In the present study the 
drug effect on a dichotomous outcome was determined. In trials with 
dichotomous outcomes the statistical power is determined by the 
proportion of patients who reach the outcome. In our prior study we 
evaluated the drug effect on the continuous outcome of percentage 
albuminuria change. In these trials the power is determined by the 
magnitude of change and standard deviation of the change. Second, 
the number of confirmation visits was different. In the current study 
we only used a single confirmation study whereas in our prior study 
we used multiple follow-up visits with urine collections. Whether 
confirmation of the transition endpoint at multiple visits would alter 
the results requires a study with multiple follow-up visits within a few 
months and this remains to be determined.
The limitations of our study are that we were only able to include 
clinical trials that assessed the effect of RAAS-intervention in patients 
with type 1 or type 2 diabetes. We do not know whether the results 
will be similar with other drugs or in other populations. To calculate 
a percentage increase in albuminuria we used the albuminuria values 
collected at a single baseline visit. Albuminuria was not assessed 
at multiple visits before randomization. We therefore do not know 
whether multiple baseline visits improved the precision in the per-
centage increase in albuminuria and the potential impact on the 
results. Finally, these results were derived post-hoc. We encourage 
clinical trialists to prospectively validate these findings. 
In conclusion, neither increasing the number of urines collected at 
a single study visit, nor the inclusion of a confirmation visit, nor the 
time to the confirmation visit, nor the addition of a minimal required 
percentage albuminuria change altered the average drug effect. 
Therefore, we conclude that future clinical trials in diabetic nephrop-
athy using albuminuria transitions as endpoint should consider 
single urine collections per study visit spaced no more than 6 months 
apart for albuminuria assessment.
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Supplementary Table 1. Association between a transition in albuminuria class (normo- to microal-
buminuria transition or micro- to macroalbuminuria transition) during the first year of the ALTITUDE 
trial with subsequent renal (doubling serum creatinine / end-stage renal disease / renal death) and 
cardiovascular (CV-death, resuscitated sudden death, myocardial infarction, stroke, unplanned hos-
pitalization for heart failure) outcomes. The definitions of albuminuria class transitions are similar as 
those that were used to assess the drug effect.
Renal outcome Cardiovascular outcome
Hazard Ratio 
(95%CI)




Single urine sample 1.92 (1.09; 3.40) 5.02 0.025 1.45 (1.15; 1.83) 9.81 0.002
Two urine samples 1.80 (1.01; 3.20) 3.98 0.046 1.30 (1.02; 1.65) 4.46 0.035
Three urine samples 1.82 (1.02; 3.24) 4.12 0.042 1.35 (1.06; 1.72) 6.00 0.014
Addition of confirmation 
visit
2.47 (1.36; 4.49) 8.81 0.003 1.42 (1.09; 1.85) 6.84 0.009
Transition  
+ 10% UACR increase 
1.94 (1.10; 3.43) 5.19 0.023 1.44 (1.14; 1.82) 9.45 0.002
Transition  
+ 20% UACR increase
1.97 (1.11; 3.48) 5.44 0.020 1.42 (1.12; 1.80) 8.65 0.003
Transition  
+ 30% UACR increase
2.06 (1.17; 3.64) 6.20 0.013 1.39 (1.10; 1.76) 7.47 0.006
Transition  
+ 40% UACR increase
2.13 (1.21; 3.76) 6.81 0.009 1.42 (1.12; 1.79) 8.43 0.004
The presented hazard ratios are derived from a Cox proportional hazard models and adjusted for 
age, gender, albumin:creatinine ratio, eGFR, systolic/diastolic blood pressure, HbA1c, and cardio-
vascular disease history.  
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Supplementary Figure 1. Magnitude and precision of the drug effect estimate with a single urine 
collection and different time-intervals between study visits. Solid circles represents the estimate of 
the treatment effect and the horizontal line indicates the 95% confidence interval.
Favours Favours
RAASi Placebo RAASi Placebo
BENEDICT
6 months 74/14.5 49/21.0
12 months 39/8.3 28/12.9
ALTITUDE
6 months 850/46.41 1011/54.6 0.79 ( 0.72 - 0.86 )
12 months 710/40.3 863/47.8 0.78 ( 0.71 - 0.87 )
IRMA-2
6 months 64/17.2 50/26.3
12 months 30/8.6 24/14.0
No / % of  events/
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 ( 0.46 - 0.99 )
0.61 ( 0.38 - 1.00 )
0.59 ( 0.41 - 0.86 )
0.52 ( 0.30 - 0.89 )
0.3 0.5 0.8 1 1.2 1.5
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